Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
The antiviral prophylaxis for cytomegalovirus infection in
allogeneic
hematopoietic cell transplantation was reviewed. Prophylaxis reduse
CMV
reactivation and disease but has little effect on OS in older
studies,
except the newly published letermovir study.
We discussed our current practice.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
A transplantational research project showing that the combined Tx
of CBU and
multiple allogeneic progenitors may facilitate early engraftment
without
affecting the long term engraftment of the single CBU.
Presenter:Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
We discussed an excellent article published in NEJM regarding the
clinical value of PDL1 expression.
Presenter:Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
The significance of HHV6 viremia was discussed.
Presenter:Prof.Spyridonidis
Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas
A study entitled "Graft-versus-host disease in recipients of
male
unrelated donor compared with parous female sibling donor
transplants"
was presented.
This was a retrospective cohort study in adults with acute
myeloid
leukemia, acute lymphoblastic leukemia, or myelodysplastic
syndrome, who
underwent T-cell replete HCT from these 2 donor types (parous
female
sibling...
A retrospective study comparing sibling vs PTCY haplo was
presented
Patient age, 18 to 54 years: comparable survival after transplants
from
an HLA-matched sibling and a haploidentical
sibling.
Patient age, 55 to 76 years: better survival after transplants from
an
HLA-matched sibling compared with offspring.
Presenter: Prof.Spyridonidis
Participants: Dr.Liga, Dr.Spyridis,...
The use of defibrotide in blood and marrow transplantation was
discussed.
Presenter: Prof. Spyridonidis
Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas
A paper in BV entitled "Prediction of cardiovascular disease
among
hematopoietic cell transplantation survivors" was
presented.
Presenter: Prof. Spyridonidis
Participants: Dr.Liga, Dr Spyridis, Dr. Aggelinas
Based on a case of our unit we discussed "Outcomes of patients
who
developed subsequent solid cancer after hematopoietic
cell
transplantation"
Presenter:Prof.Spyridonidis
Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas
A paper published in Blood Advances and entitled "How ibrutinib,
a
B-cell malignancy drug, became an FDA-approved second-line therapy
for
steroid-resistant chronic GVHD" was presented.
Presenter:Prof.Spyridonidis
Participants:Dr Liga, Dr Spyridis, Dr Aggelinas
An excellent review/focus from R Storb.
His fazit,
" Therefore, faced with the choice of an HLA-identical sibling
marrow
graft or even an alternative donor graft vs immunosuppression,
many
patients should be counseled in favor of marrow transplantation
as
first-line therapy."
Presenter:Prof. Spyridonidis
Participants:Dr. Liga, Dr.Spyridis, Dr Aggelinas
A recent study published in Blood advances "Evaluation of
induction
chemotherapies after hypomethylating agent failure in
myelodysplastic
syndromes and acute myeloid leukemia" was
presented.
Induction led to response in 41% and 32%, survival of 10.8 and 6
months,
and transplant in 40% and 42% of responders in MDS...
We discussed the emerging data of the importance of asparaginase in
the
treatment of ALL. We discussed the potential toxicities and how we
can
manage them. The time point of application plays after cheotherpay
is of
major importance. Monitoring for pancreatitis and bleeding should
be
done routinely.
Presenter: Prof....
We discussed the current literature regarding the role of allo HCT
in
the era of BV and PD1 blockade for HD.
Patients with cHL who are ineligible for auto-HCT or relapse
after
auto-HCT have historically had a poor prognosis with a median
survival
of 2 years or...
A patient with JAkavi resistant LF who was referred to our unit
was
presented and discussed. We also presented the current How I treat
paper
form Blood.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
The Oncopedia 2018 update on CLL treatment algorithm has presetend
and
discussed.
Presenter: Prof. Spyridondis
Partricpants: Dr Liga, Dr Spyridis, Dr Aggelinas
Presenter: Prof. Spyridonidis
Participants:Dr Liga, Dr Spyridis, Dr Aggelinas
Main
studies in newly diagnosed MM (NDMM) presented in 23. Congress,
European Hematology Association (EHA), Stockholm,
Sweden.
ALCYONE
NDMM, >65y, auto non-eligible
Daratumumab (D) plus Bortezomib-Melphalan-Prednison (VMP)
vs VMP
more CR, PFS nr vs 20,4 Mo, no problems with addtion
of Daratumumab
GIMEMA
Phase-3, NDMM
Bortezomib, Thalidomid-Dexamethason (VTD) vs TD, pre...
Presenter: Dr Liga
Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr
Aggelinas
The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was
presented.
Presenter: Prof:Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal of the educational session is to understand the role of DPB1
mismatched in allo Tx. We discussed their level of expression
and their alloreactivity as is scored in the TCE algorithm.
We also discussed a new proposed methodology which defines the DPB1
alloreactivity...